SG11202010763VA - Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade - Google Patents

Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade

Info

Publication number
SG11202010763VA
SG11202010763VA SG11202010763VA SG11202010763VA SG11202010763VA SG 11202010763V A SG11202010763V A SG 11202010763VA SG 11202010763V A SG11202010763V A SG 11202010763VA SG 11202010763V A SG11202010763V A SG 11202010763VA SG 11202010763V A SG11202010763V A SG 11202010763VA
Authority
SG
Singapore
Prior art keywords
natural killer
chimeric antigen
immune checkpoint
killer cells
antigen receptors
Prior art date
Application number
SG11202010763VA
Other languages
English (en)
Inventor
May Daher
Rafet Basar
Elizabeth Shpall
Katy Rezvani
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11202010763VA publication Critical patent/SG11202010763VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11202010763VA 2018-05-03 2019-05-03 Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade SG11202010763VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666665P 2018-05-03 2018-05-03
US201862666965P 2018-05-04 2018-05-04
PCT/US2019/030721 WO2019213610A1 (en) 2018-05-03 2019-05-03 Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade

Publications (1)

Publication Number Publication Date
SG11202010763VA true SG11202010763VA (en) 2020-11-27

Family

ID=68386134

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010763VA SG11202010763VA (en) 2018-05-03 2019-05-03 Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade

Country Status (13)

Country Link
US (1) US20210230548A1 (enExample)
EP (1) EP3788061A4 (enExample)
JP (2) JP2021522798A (enExample)
KR (1) KR20210005240A (enExample)
CN (1) CN112292390A (enExample)
AU (1) AU2019262218B2 (enExample)
BR (1) BR112020022010A2 (enExample)
CA (1) CA3099342A1 (enExample)
CO (1) CO2020015168A2 (enExample)
MX (1) MX2020011697A (enExample)
NZ (1) NZ770183A (enExample)
SG (1) SG11202010763VA (enExample)
WO (1) WO2019213610A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918028B (zh) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
MX356586B (es) 2011-07-11 2018-06-05 Takeda Vaccines Inc Formulaciones parenterales de vacunas contra los norovirus.
JP2020517259A (ja) * 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CN111565730B (zh) * 2017-11-09 2024-09-17 桑格摩生物治疗股份有限公司 细胞因子诱导型含sh2蛋白（cish）基因的遗传修饰
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
WO2019222503A1 (en) * 2018-05-16 2019-11-21 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
KR20220004992A (ko) * 2019-03-29 2022-01-12 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Car-nk 세포의 생산 방법 및 이의 용도
AU2020288829A1 (en) * 2019-06-04 2021-12-02 Nkarta, Inc. Combinations of engineered natural killer cells and engineered T cells for immunotherapy
EP4045083B1 (en) 2019-10-18 2024-01-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
US12195723B2 (en) * 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
CN115925976A (zh) * 2019-11-21 2023-04-07 博生吉医药科技(苏州)有限公司 Cd7-car-t细胞及其制备和应用
CA3162901A1 (en) * 2019-11-27 2021-06-03 Board Of Regents, The University Of Texas System Large-scale combined car transduction and crispr gene editing of msc cells
BR112022010225A2 (pt) * 2019-11-27 2022-09-06 Univ Texas Transdução de car combinado em grande escala e edição de gene crispr de células nk
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
WO2021142127A1 (en) * 2020-01-08 2021-07-15 Board Of Regents, The University Of Texas System A method of engineering natural killer cells to target cd70-positive tumors
WO2021202581A1 (en) * 2020-03-30 2021-10-07 WUGEN, Inc. Engineered immune cells for adoptive cell therapy
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392809A1 (en) * 2020-12-03 2023-07-20 Nkarta, Inc. Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
CA3201621A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
EP4262825A1 (en) 2020-12-15 2023-10-25 Universiteit Antwerpen Cell-based therapeutics targeting cd70
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CN113005151A (zh) * 2021-03-12 2021-06-22 广东药科大学 一种kdr-car-nk细胞的制备方法及其应用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
KR20240010717A (ko) * 2021-05-20 2024-01-24 우시 바이올로직스 아일랜드 리미티드 유전적으로 변형된 nk 세포들 및 이들의 용도
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
CN113599395B (zh) * 2021-09-22 2022-08-12 郑州源创吉因实业有限公司 含有nk细胞的治疗癌症的药物组合物
JP2024536279A (ja) * 2021-10-01 2024-10-04 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 抗体を担持した免疫細胞及び癌治療における使用方法
WO2023062113A1 (en) * 2021-10-15 2023-04-20 Miltenyi Biotec B.V. & Co. KG Method for the generation of genetically modified nk cells
CN118355023A (zh) * 2021-10-21 2024-07-16 得克萨斯大学体系董事会 具有增强的代谢适应性的治疗性免疫细胞的生产方法及其组合物
WO2023081811A1 (en) * 2021-11-04 2023-05-11 Saliogen Therapeutics, Inc. Immune cells with chimeric antigen receptors or chimeric autoantibody receptors
UY40023A (es) 2021-11-18 2023-05-31 Janssen Biotech Inc Métodos de cultivo celular sin alimentadora para la expansión de preparaciones de células destructoras naturales
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CN118256444A (zh) * 2022-04-26 2024-06-28 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
AR130860A1 (es) * 2022-10-25 2025-01-29 Takeda Pharmaceuticals Co Composiciones de linfocitos nk del receptor quimérico adgre2 y métodos de uso
JP2025536042A (ja) * 2022-11-10 2025-10-30 オーエヌケイ セラピューティクス リミテッド 免疫調節薬を用いた併用療法
CN115947869B (zh) * 2022-11-28 2023-12-12 广州佰芮慷生物科技有限公司 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途
CN115948344A (zh) * 2023-02-10 2023-04-11 上海交通大学 嵌合抗原受体nk细胞、制备方法及其用途
KR20250166262A (ko) * 2023-03-24 2025-11-27 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 향상된 항종양 기억 반응을 갖는 조작된 자연 살해 세포
AU2024253315A1 (en) * 2023-04-07 2025-10-16 Nkarta, Inc. Methods for treatment of autoimmune diseases
CN116769722B (zh) * 2023-07-04 2024-07-16 杭州荣谷生物科技有限公司 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025073908A1 (en) * 2023-10-05 2025-04-10 Onk Therapeutics Limited Optimised il-15 constructs
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2614151B1 (en) * 2010-09-08 2019-07-24 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
US20140255363A1 (en) * 2011-09-16 2014-09-11 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
JP6010136B2 (ja) * 2011-12-22 2016-10-19 モガム バイオテクノロジー インスティチュート ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物
WO2017023803A1 (en) * 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
CN112972492B (zh) * 2015-12-16 2024-11-08 沃尔特及伊莱萨霍尔医学研究院 Nk细胞中对细胞因子诱导的sh2蛋白的抑制
EP3901258A1 (en) * 2016-01-11 2021-10-27 The Board of Trustees of the Leland Stanford Junior University Chimeric proteins and methods of immunotherapy
WO2017123956A1 (en) * 2016-01-15 2017-07-20 Etubics Corporation Methods and compositions for t-cell immunotherapy
EP3463440A4 (en) * 2016-05-27 2020-04-15 Etubics Corporation NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
WO2018081476A2 (en) * 2016-10-27 2018-05-03 Intima Bioscience, Inc. Viral methods of t cell therapy
JP2020517259A (ja) * 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
KR20220004992A (ko) * 2019-03-29 2022-01-12 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Car-nk 세포의 생산 방법 및 이의 용도

Also Published As

Publication number Publication date
US20210230548A1 (en) 2021-07-29
AU2019262218B2 (en) 2025-04-24
JP2021522798A (ja) 2021-09-02
WO2019213610A1 (en) 2019-11-07
NZ770183A (en) 2025-05-02
BR112020022010A2 (pt) 2021-01-26
KR20210005240A (ko) 2021-01-13
CA3099342A1 (en) 2019-11-07
CO2020015168A2 (es) 2021-09-09
MX2020011697A (es) 2020-12-10
CN112292390A (zh) 2021-01-29
EP3788061A4 (en) 2022-02-23
EP3788061A1 (en) 2021-03-10
AU2019262218A1 (en) 2020-12-10
JP2024045179A (ja) 2024-04-02

Similar Documents

Publication Publication Date Title
SG11202010763VA (en) Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
IL268881A (en) Use of anti-CTLA-4 antibodies with increased ADCC, to increase the immune response to vaccine-A
IL278879B2 (en) Chimeric antigen receptor with antigen binding regions to the T cell receptor beta constant region
EP3612210A4 (en) IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
IL269553A (en) Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
IL250831A0 (en) Antibodies and chimeric antigen receptors specific for cd19, compositions containing same and uses thereof
EP3313892A4 (en) Immune checkpoint chimeric antigen receptors therapy
EP3880247A4 (en) Bispecific antibodies for activation of immune cells
IL242315B (en) Transgenic immune activator cells of chimeric antigen receptor specific for cs1
PL3227432T3 (pl) Chimeryczne receptory antygenowe ukierunkowane na antygen dojrzewania komórek b i ich zastosowania
EP3240805A4 (en) Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
IL247740A0 (en) Antibodies that bind to cd3 epsilon from human and cynomolgus
MY175869A (en) Compositions and methods for immunotherapy
GB201600328D0 (en) Anti-CD37 chimeric antigen receptors and immune cells expressing them
IL279310A (en) CD79A chimeric antigen receptors
IL257295B (en) Chimeric antigen receptors, and T cells in which expression of a chimeric antigen receptor is measured
SG11201604565WA (en) Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
EP3131917A4 (en) Humanized and chimeric monoclonal antibodies to cd99
IL289921A (en) Cells express chimeric antigen receptors and chimeric stimulatory receptors and their functions
IL274258B (en) Chimeric antigen receptors that bind to ssea4 and their uses
HK40039976A (en) Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade